Abstract
Objective The aim of this study is to evaluate the differences of clinical presentations and the impact of healthcare organization on outcomes of neurological COVID-19 patients admitted during the first and second pandemic waves.
Methods In this single center cohort study, we included all patients with SARS-CoV-2 infection admitted to a Neuro-COVID Unit. Demographic, clinical and laboratory data were compared between patients admitted during the first and second waves of COVID-19 pandemic.
Results 223 patients were included, of whom 112 and 111 hospitalized during the first and second pandemic waves, respectively. Patients admitted during the second wave were younger and exhibited pulmonary COVID-19 severity, resulting in less oxygen support (n=41, 36.9% vs n=79, 70.5%, p<0.001) and lower mortality rates (14.4% vs 31.3%, p=0.004). The different healthcare strategies and early steroid treatment emerged as significant predictors of mortality independently from age, premorbid conditions and COVID-19 severity in cox regression analyses.
Conclusions Differences in healthcare strategies during the second phase of COVID-19 pandemic probably explain the differences in clinical outcomes independently of disease severity, underlying the importance of standardized early management of neurological patients with SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of University of Brescia gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial disclosure and conflict of interest regarding the research related to the manuscript: All authors have no conflict of interest regarding the research related to the manuscript. The full financial disclosure for the past year (for all authors) is documented at the end of the manuscript.
Study funding: The study was not financial supported
Competing interest V. Cristillo, A. Benussi, I. Libri, M. Giunta, A. Morotti, S. Gipponi, M. Locatelli, S. Cotti Piccinelli, V. Mazzoleni, F. Schiano di Cola, S. Masciocchi, D. Pezzini, A. Scalvini, E. Premi, E. Cottini, M. Gamba, M. Magoni, M. M. Fontanella report no disclosures relevant to the manuscript. Andrea Pilotto received speaker honoraria and travel grants from AbbVie Pharmaceuticals BioMarin Pharmaceutical, Chiesi Pharmaceuticals, Nutricia Pharmaceuticals, UCB Pharma and Zambon Pharmaceuticals. Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly, and Actelion Ltd Pharmaceuticals; and received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma, and Chiesi Pharmaceuticals.
Data Availability
All data produced in the present work are contained in the manuscript
